Campaigners have urged AstraZeneca to disclose its plans to develop a coronavirus vaccine and guarantee that it will be patent-free, after a number of pharmaceutical giants snubbed the scheme set up by the World Health Organisation (WHO) to share trial data and intellectual property (IP) rights.
AstraZeneca first teamed up with Oxford University in April to produce and distribute a Covid-19 vaccine, before announcing last week that it had partnered with British cell-therapy company Oxford Biomedica to bolster its manufacturing capacity to produce 1 billion doses.
The Cambridge-based pharmaceutical group, whose market value has surged over the past month, has already received orders from the UK and US governments for its vaccine candidate, called AZD1222.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies